帕米磷酸二钠治疗绝经后骨质疏松症患者的临床疗效观察

目的观察帕米磷酸二钠防治绝经后骨质疏松症患者的疗效。方法将63例绝经后骨质疏松症患者随机分为两组,对照组采用口服凯思立D、罗盖全和仙灵骨葆胶囊治疗,治疗组采用静滴帕米磷酸二钠和口服凯思立D、罗盖全、仙灵骨葆胶囊治疗,分别治疗6个月。在治疗前、治疗1个月、3个月、6个月分别进行VAS疼痛评分,以及治疗前、治疗6个月进行腰椎L1-4骨密度(BMD)检测。结果治疗1个月和3个月,两组VAS评分较治疗前有不同程度降低,且治疗组止痛效果优于对照组(P0.05);治疗6个月,两组VAS评分均明显降低,但两组VAS评分无统计学差异(P0.05)。治疗6个月,两组腰椎L1-4骨密度较治疗前明显提高(P0.05),且治疗组优于对照组(P0.05)。结论帕米磷酸二钠可有效缓解绝经后骨质疏松症患者的疼痛,并且能提高患者的骨密度。

EFFICACY OF PAMIDRONATE ON OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

Objective: To observe the effect of Pamidronate on the prevention and treatment of postmenopausal osteoporosis. Methods: A total of 63 postmenopausal women with osteoporosis were randomly divided into two groups. The control group was treated with oral Calcium Carbonate and Vitamin D3, Calcitriol Soft Capsules and XianLingGuBao capsule. The treatment group was treated with intravenous Pamidronate combined with oral Calcium Carbonate, Vitamin D3, Calcitriol Soft Capsules and XianLingGuBao capsule. VAS pain score were measured before and 1, 3, 6 months after the experiment. Bone mineral density (BMD) of the lumbar spine 1-4 were measured before and 6 months after the experiment. Results: After 1 and 3 months of the treatment, the VAS scores in both groups decreased in different degrees. The treatment effect of bone pain in the treatment group was significantly better than that in the control group (P<0.05). After 6 months of the treatment, the VAS scores in both groups decreased in significant degrees. But there was no significant difference in bone pain between two groups(P>0.05). BMD of L1-4, femoral neck area increased significantly in the two groups after 6 months of the treatment (P<0.05). The effect in the treatment group was significantly better than that in the control group (P<0.05). Conclusion: Pamidronate effectively relieves bone pain and improve bone mineral density in postmenopausal osteoporosis patient.